Source-grounded facts extracted from Amphastar Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Amphastar Pharmaceuticals, Inc. shareholders approved Advisory vote on frequency of future stockholder advisory votes on named executive officer compensation.
“4. Advisory Vote on the Frequency of Future Stockholder Advisory Votes on Named Executive Officer Compensation 1 Year 2 Years 3 Years Abstained Broker Non-votes 33,816,071 12,329 1,624,016 24,576 4,439,978”
Amphastar Pharmaceuticals, Inc. shareholders approved Advisory vote on compensation of named executive officers.
“3. Advisory Vote on the Compensation of our Named Executive Officers For Against Abstained Broker Non-votes 32,585,908 2,779,281 111,803 4,439,978”
Amphastar Pharmaceuticals, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm.
“2. Ratification of Appointment of Independent Registered Public Accounting Firm For Against Abstained Broker Non-votes 39,179,786 684,828 52,356 N/A”
Amphastar Pharmaceuticals, Inc. shareholders approved Election of three Class I directors.
“1. Election of Directors Nominee For Against Abstained Broker Non-votes David Gaugh 35,242,863 209,084 25,045 4,439,978 William J. Peters 23,652,131 11,785,772 39,089 4,439,978 Jacob Liawatidewi 23,224,791 12,212,988 39,213 4,439,978”
Amphastar Pharmaceuticals, Inc. reported three months ended March 31, 2026 results: net income Adjusted non-GAAP net income of $19.5 million, EPS $0.42 per share.
“of $171.2 million for the three months ended March 31, 2026 - GAAP net income of $6.4 million, or $0.14 per share, for the first quarter - Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter - Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA – May 7, 2026 – Amphastar Pharmaceuticals,”
Amphastar Pharmaceuticals, Inc. amended Contract Research Amendment with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at approximately $0.6 million (effective 2026-03-03).
“On March 3, 2026 (the “Effective Date”), Amphastar Pharmaceuticals, Inc (“Amphastar” or, the “Company”) and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (“Hanxin”) entered into an amendment (the “Contract Research Amendment”) to the Contract Research Agreement (the “Contract Research Agreement”), originally entered into on September 15, 2025, as previously reported by the Company on a Current Report on Form 8-K filed on September 18, 2025.”
Amphastar Pharmaceuticals, Inc. entered into Supply Agreement with Nanjing Letop Biotechnology Co., Ltd. (effective 2026-03-03).
“On March 3, 2026, (the “Effective Date”), Amphastar Nanjing Pharmaceuticals, Inc. (“ANP”), the Chinese subsidiary of Amphastar Pharmaceuticals, Inc. (“Amphastar” or, the “Company”), entered into a supply agreement (the “Supply Agreement”) with Nanjing Letop Biotechnology Co., Ltd. (“Letop”).”
Amphastar Pharmaceuticals, Inc. amended Manufacturing Amendment with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at Change in value not determinable; expands territory globally except US and Canada for Lidocaine and (effective 2026-01-06).
“On January 6, 2026, Amphastar Nanjing Pharmaceuticals, Inc., the Chinese subsidiary of Amphastar and Hanxin entered into an amendment to the Manufacturing Agreement (the “Manufacturing Amendment”), originally entered into on April 19, 2022, as previously reported by the Company on a Current Report on Form 8-K filed on April 22, 2022.”
Amphastar Pharmaceuticals, Inc. amended Distribution Amendment with Hong Kong Genreach Limited valued at Change in value not determinable; expands region with additions of Middle East and Southeast Asian c (effective 2026-01-06).
“On January 6, 2026, Armstrong Pharmaceuticals, Inc. a wholly-owned subsidiary of the Amphastar and Hong Kong Genreach Limited (“Genreach”) a wholly-owned subsidiary of Hanxin entered into an amendment to the Distribution Agreement (the “Distribution Amendment”), originally entered into on August 28, 2024, as previously reported by the Company on a Current Report on Form 8-K filed on August 30, 2024 (the “Distribution Agreement”).”
Amphastar Pharmaceuticals, Inc. entered into License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at Amphastar made an upfront payment of $2 million; development milestone payments up to $14 million; s (effective 2026-01-06).
“On January 6, 2026, Amphastar Pharmaceuticals, Inc (“Amphastar” or, the “Company”), and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (“Hanxin”), entered into a License Agreement (“License Agreement”) pursuant to which Hanxin is granting an exclusive license to certain intellectual property controlled by Hanxin to develop, make, use and commercialize products incorporating or comprising of corticotropin compound (“Licensed Product”) in the United States and Canada (the “Territory”).”
Amphastar Pharmaceuticals, Inc.: Approved amendment to Bylaws to clarify exclusive forum selection for certain legal actions (effective 2025-06-02).
“the board of directors of the Company approved an amendment to the amended and restated bylaws of the Company (the “Bylaws” and such amendment, the "Bylaws Amendment”) clarifying that unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court in Delaware or the United States District Court for the District of Delaware) and any appellate court therefrom will be the sole and exclusive forum”
Amphastar Pharmaceuticals, Inc.: Approved amendment to Charter to remove forum selection provision (effective 2025-06-02).
“and (ii) to remove the forum selection provision (the “Forum Selection Amendment,” and together with the Exculpation Amendment, the “Charter Amendments”).”
Amphastar Pharmaceuticals, Inc.: Approved amendment to Charter to include officer exculpation provisions under Delaware law (effective 2025-06-02).
“the stockholders of the Company voted on and approved amendments to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) (i) to reflect Delaware law provisions regarding officer exculpation (the “Exculpation Amendment”);”
Amphastar Pharmaceuticals, Inc. reported the three months ended March 31, 2024 results: revenue $171.8 million, net income $43.2 million, EPS $0.81 per share.
“Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2024. First Quarter Highlights ● Net revenues of $171.8 million for the first quarter ● GAAP net income of $43.2 million, or $0.81 per share, for the first quarter”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.